Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Leukemia, Myeloid, Acute 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Cholangiocarcinoma 1Carcinoma 1

Interventions

Gemcitabine 6Cisplatin 6Magnetic Resonance Spectroscopy 5Specimen Handling 4Capecitabine 4Biopsy 3pembrolizumab 2durvalumab 2Trastuzumab 2Platinum 2Oxaliplatin 2Leucovorin 2Fluorouracil 21,2-diaminocyclohexaneplatinum II citrate 2varlilumab 1tucatinib 1toripalimab 1peposertib 1guadecitabine 1dehydroftorafur 1cobimetinib 1binimetinib 1avelumab 1atezolizumab 1Tegafur 1Taxes 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiation Dose Hypofractionation 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Gallbladder Neoplasms × peposertib × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡